Using Prophylactic Antihemorrhagic Medications in Second-Trimester Surgical Abortions.

Obstet Gynecol

Department of Obstetrics and Gynecology and Aurora University of Wisconsin Medical Group, Advocate Aurora Health, Aurora Sinai Medical Center, the Center for Urban Population Health, the Advocate Aurora Research Institute, and the Department of Oncology, Advocate Aurora Health, Aurora West Allis Medical Center, Milwaukee, Wisconsin.

Published: October 2022

We aimed to estimate the association of prophylactic antihemorrhagic medication use during dilation and evacuation (D&E) with operative hemorrhage and estimated blood loss (EBL). Records for all pregnant patients between 14 and less than 22 weeks of gestation who had a D&E procedure from January 2012 to December 2019 were retrospectively reviewed. Prophylactic antihemorrhagic medication use was defined as receiving vasoconstrictors, uterotonics, or both before identification of hemorrhage during a D&E procedure. Overall, 147 D&E procedures were completed at a mean of 16.4 (±2.2) weeks of gestation. Prophylactic medications were used in 72.1% (n=106) of D&E procedures. Prophylactic medication use was associated with lower operative hemorrhage (21.7% vs 51.2%, P <.01) and lower EBL (336.9 mL vs 551.3 mL, P <.01).

Download full-text PDF

Source
http://dx.doi.org/10.1097/AOG.0000000000004922DOI Listing

Publication Analysis

Top Keywords

prophylactic antihemorrhagic
12
antihemorrhagic medication
8
operative hemorrhage
8
weeks gestation
8
d&e procedure
8
d&e procedures
8
prophylactic
5
d&e
5
antihemorrhagic medications
4
medications second-trimester
4

Similar Publications

Lung inflammation is a hallmark of several respiratory diseases. Despite the great effectiveness of the synthetic antiinflammatory agents, they cause potential side effects. Polydatin (PD), a natural phytomedicine, has antioxidant and antiinflammatory effects.

View Article and Find Full Text PDF

Rationale: Postpartum haemorrhage (PPH) is common and potentially life-threatening. The antifibrinolytic drug tranexamic acid (TXA) is thought to be effective for treating PPH. There is growing interest in whether TXA is effective for preventing PPH after vaginal birth.

View Article and Find Full Text PDF

: This systematic review evaluates the effectiveness of various hematological treatment protocols and local hemostatic measures in preventing oral bleeding and other complications during and after dental treatments in children with inherited bleeding disorders and inhibitors. : This study was registered in the PROSPERO database. The comprehensive search strategy for this systematic review was conducted across five databases, namely, PubMed, Google Scholar, Web of Science, Scopus, and Cochrane Library.

View Article and Find Full Text PDF
Article Synopsis
  • Background: The study focused on the effectiveness of tranexamic acid in preventing bleeding and reducing the need for platelet transfusions in patients with blood cancers receiving intensive treatment.
  • Methods: An international trial (TREATT) involved 616 adults under chemotherapy or stem-cell transplant, who were randomly assigned to receive either tranexamic acid or a placebo while monitored for bleeding and platelet recovery.
  • Findings: Out of 1736 screened patients, 597 were included in the final analysis, revealing demographic details and outcomes related to bleeding events and mortality rates among the two groups.
View Article and Find Full Text PDF

Myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) are severe myeloid disorders associated with significant morbidity and mortality. Because of patient and disease factors, many older adults are treated as outpatients with less-intensive therapy. Optimal supportive care strategies to minimize bleeding and infectious complications in this patient population have not been systematically evaluated.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!